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Summary 
The secreted form of l~-amyloid precursor protein 
(APP) containing the Kunitz proteinase inhibitor (KPI) 
domain, also called protease nexin II, is internalized 
and degraded by cells. We show that the low density 
lipoprotein (LDL) receptor-related protein (LRP) is 
responsible for the endocytosis of secreted APP. 
APPs770 degradation is inhibited by an LRP antagonist 
called the receptor-associated protein (RAP) and by 
LRP antibodies and is greatly diminished in fibroblasts 
genetically deficient in LRP. APPs695, which lacks the 
KPI domain, is s poor LRP ligand. Since LRP also binds 
apolipoprotein E (apoE)-enriched lipoproteins and in- 
heritance of the ~4 allele of the apoE gene is a risk 
factor for Alzheimer's disease (AD), these data link in 
a single metabolic pathway two molecules strongly im- 
plicated in the pathophysiology of AD. 
Introduction 
Alzheimer's disease (AD) is a late-onset neurodegenera- 
tive disorder characterized by the extracellular deposition 
of insoluble aggregates composed of the 40-42 amino 
acid A~ peptide in the brain (Glenner and Wong, 1984; 
Masters et al., 1985). AI3 peptide is derived from an integral 
membrane protein termed I~-amyloid precursor protein 
(APP) (Tanzi et al., 1987; Kang et al., 1987). The function 
and metabolism of APP have been the subject of intensive 
study owing to the fact that mutations in APP are associ- 
ated with an autosomal dominant form of AD (Goate et al., 
1991) and that overproduction of APP is the presumptive 
cause of AD in trisomy 21 (Tanzi et al., 1987; Hyman et 
al., 1995). Multiple APP isoforms can be generated by 
alternative splicing of mRNAs. The major isoforms in brain 
are APP695, APP751, and APP770 containing 695, 751, 
and 770 amino acids, respectively. These isoforms are 
transmembranous proteins having large extracellular re- 
*The first wo authors contributed equally to this work. 
gions, with hydrophobic membrane-spanning domains 
and short cytoplasmic segments. APP is also a member 
of an evolutionary conserved family of proteins that include 
the APP-like proteins, APLP1 and APLP2 (Wasco et al., 
1992, 1993; Slunt et al., 1994). 
Secreted forms of APP are generated by proteolytic 
cleavages within their extracellular domain close to the 
transmembrane region. The extracellular regions of 
APP751, APP770, and APLP2 each contain a Kunitz prote- 
ase inhibitor (KPI) domain encoded by an alternatively 
transcribed exon (Kitaguchi et al., 1988; Tanzi et al., 1988; 
Wasco et al,, 1993; Slunt et al., 1994). Secreted forms 
of APP having the KPI domain correspond to a protease 
inhibitor that has been identified separately and named 
protease nexin II (APP/PN-2) (Van Nostrand and Cunning- 
ham, 1987; Oltersdorf et al., 1989; Van Nostrand et al., 
1989), a potent inhibitor of the blood coagulation factors 
IXa (Schma, ier et al., 1993) and Xla (Van Nostrand et al., 
1990). APP/PN-2 binds with high affinity to cultured fibro- 
blasts (Johnson-Wood et al., 1994), and APP/PN-2-pro- 
teinase complexes are internalized and degraded by cul- 
tured cells (Knauer and Cunningham, 1982; Knauer et al., 
1983), although the mechanism for this process is un- 
known. Recent studies have identified the low density lipo- 
protein (LDL) receptor-related protein (LRP) as the recep- 
tor responsible for the catabolism of another Kunitz-type 
inhibitor, tissue factor pathway inhibitor (TFPI) (Warshaw- 
sky et al., 1994). 
LRP is a large multiligand receptor (Krieger and Herz, 
1994; Strickland et al., 1995) that is a member of the LDL 
receptor family, which also includes the LDL receptor (Ya- 
mamoto et al., 1984), the very low density lipoprotein 
(VLDL) receptor (Takahashi et al., 1992), and glycoprotein 
330 (gp330) (Saito et al., 1994). A 39 kDa protein, termed 
the receptor-associated protein (RAP) (Strickland et al., 
1991), binds to members of the LDL receptor family (Wil- 
liams et al., 1992; Kounnas et al., 1992a; Battey et al., 
1994) and blocks their ligand binding capacity. LRP medi- 
ates the cellular uptake and subsequent degradation of 
proteinases, such as tissue-type plasminogen activator 
(Bu et al., 1992) and urokinase-type plasminogen activator 
(Kounnas et al., 1993); proteinase-inhibitor complexes, 
such as ~2-macroglobulin (~2M)-proteinase complexes 
(Ashcom et al., 1990; Moestrup and Gliemann, 1989); ser- 
pin-proteinase complexes (Orth et al., 1992; Nykjaer et 
al., 1992; Poller et al., 1995); matrix proteins, such as 
thrombospondin (Mikhailenko et al., 1995); apolipoprotein 
E (apoE)-enriched lipoproteins (Kowal et al., 1990; Beisie- 
gel et al., 1989); hepatic lipase (Kounnas et al., 1995); and 
lipoprotein lipase (Chappell et al., 1993). 
LRP is expressed in many tissues and is a major apoE 
receptor in the central nervous system (Rebeck et al., 
1993). Genetic data implicate inheritance of the e4 allele 
of apoE as a risk factor in AD (Strittmatter et al., 1993; 
Rebeck et al., 1993; Poirier et al., 1993; Saunders et al., 
1993). A possible involvement of LRP in AD is suggested 
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Figure 1. Analysis of Purified APP Isoforms by Immunoblotting 
APP,770 (lane 1) and APP,695 (lane 2) were electrophoresed in the 
presence of SDS on 4%-12% polyacrylamide gradient gels under 
nonreducing conditions, transferred to nitrocellulose, and stained with 
monoclonal antibodies to APP. (A) shows immunoblotting analysis us- 
ing the KPI domain-specific monoclonal antibody 7H5. (B) shows an 
immunoblot using the APP monoclonal antibody 22Cl l .  In (C), the 
filter is stained with the monoclonal antibody AIz 90 generated to a 
synthetic peptide corresponding to amino acid residues 511-608 of 
APP. The migration position of molecular mass standards are indi- 
cated on the right in kilodaltons. 
in part by the observation that LRP, as well as apoE and 
other LRP ligands, decorates enile plaques (Rebeck et 
al., 1995). 
The ability of LRP to mediate the cellular catabolism of 
TFPI, a KPI-containing protein, led us to investigate the 
role of LRP in the catabolism of APPs770. In this paper 
we present evidence that LRP is capable of binding and 
We hypothesized that, like TFPI, APP, which contains a 
KPI domain, could be catabolized by LRP. To test this 
hypothesis, we purified APPs770 and APPs695 to homoge- 
neity from cell cu Iture supernatant of cells transfected with 
APP770 or APP695 cDNA, respectively (Sisodia et al., 
1990). Amino-terminal sequencing of purified APPs770 
showed identity with residues 18-28 in APP, which corre- 
sponds to the amino-terminal sequence of the mature pro- 
tein. APP,770 migrated with an apparent molecular mass 
of 110-120 kDa and was recognized by antibodies spe- 
cific for KPI-containing APP (Figure 1A, lane 1). Purified 
APP,695 had an apparent molecular mass of 100-110 
kDa and was not reactive against KPI-specific antibodies 
(Figure 1A, lane 2). Both APP,770 and APPs695 were de- 
tected by antibodies known to recognize both forms of 
APP (Figures 1B and 1C). 
Initial experiments compared the cell-mediated degra- 
dation of ~2Sl-labeled APP,770 and APP,695 in mouse em- 
bryonic fibroblasts hat contain LRP with their catabolism 
in mouse embryonic fibroblasts that are genetically defi- 
cient in LRP (Willnow and Herz, 1994). The iodinated pro- 
teins migrated as single bands of the expected molecular 
mass when analyzed by SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) (inset in Figure 2B). For the cell- 
mediated degradation experiments, increasing concentra- 
tions of ~2Sl-labeled APPs770 (Figures 2A and 2B) and 
~2Sl-labeled APP,695 (Figures 2C and 2D) were incubated 
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Figure 2. ~2SI-Labeled APPs770 Is Degraded 
by LRP-Expressing Cells but Not LRP- 
Deficient Cells 
Wells containing 2 x 105 LRP-expressing 
(MEF) or LRP-deficient (PEA13) cells were in- 
cubated with various concentrations (0.37-10 
nM) of ~2~l-labeled APPs770 (A and B) or 12Sl- 
labeled APPs695 (C and D) for 10 hr at 37°C 
in the absence of competitor (closed circles) or 
in the presence of either 1 I~M RAP (open cir- 
cles) or 100 p,g/ml heparin (open squares). The 
cellular degradation of ~251-1abeled APP,770 by 
LRP-expressing MEF cells is shown in (A) and 
by LRP-deficient PEA13 cells in (B). The cellu- 
lar degradation of 12q-labeled APP,695 by LRP- 
expressing cells is depicted in (C) and by LRP- 
deficient cells in (D). Plotted values represent 
means of duplicate determinations. The inset 
in (B) shows autoradiogram of ~251-iabeled 
APPs770 (lane 1) and APP,695 (lane 2). The 
migration position of molecular mass stan- 
dards are indicated on the right in kilodaltons. 
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Figure 3. LRP-Deficient Cells Internalize and 
Degrade l~l-Labeled LDL, but Not l~l-Labeled 
a2M 
Wells containing 2 x 105 LRP-expressing 
(closed circles) or LRP-deficient (open circles) 
mouse fibroblasts were incubated with 1251- 
labeled LDL (8 p.g/ml) or 12Sl-labeled a2M* (1.4 
nM) for selected time intervals. Specific inter- 
nalization and degradation were determined by 
incubation of l~51-1abeled ligand in the presence 
of a 200-fold excess unlabeled ligand. Shown 
are the amounts of 12Sl-labeled LDL internalized 
(A) and degraded (B) and of lZSl-labeled a=M* 
internalized (C) and degraded (D). The plotted 
values represent means of duplicate determi- 
nations. 
with fibroblasts for 10 h r, after which the extent of degrada- 
tion was determined by measuring the amount of acid 
soluble radioactivity present in the medium. 12Sl-labeled 
APP,770 was readily degraded in a dose-dependent man- 
ner when added to LRP-expressing cells (Figure 2A). In 
contrast, fibroblasts derived from mouse embryos that are 
genetically deficient in LRP were unable to degrade 12% 
labeled APPs770 (Figure 2B). These data provide convinc- 
ing evidence that LRP is responsible for mediating the 
uptake of APP,770, leading to its degradation. Unlike 
APP,770, 12Sl-labeled APP,695 is not efficiently degraded 
in LRP-expressing fibroblasts (Figure 2C), indicating that 
the KPI-containing form of APP is the preferred ligand. 
When experiments were conducted at high APP,770 con- 
centrations (30 nM) and degradation measured after 18 
hr, some APP,770 was degraded in a RAP-independent, 
but heparin- and chloroquine-dependent, manner in LRP- 
deficient cells (data not shown), suggesting that an addi- 
tional pathway may exist for the uptake and degradation 
APPs770. 
We also used an LRP antagonist, the 39 kDa RAP, to 
confirm that LRP is mediating the uptake of APP,770. 
RAP, a protein that was initially identified when it copuri- 
fled with LRP (Ashcom et al., 1990), binds members of the 
LDL receptor family and antagonizes their ligand-binding 
activity, preventing them from internalizing ligands (Herz 
et al., 1991; Williams et al., 1992; Willnow et al., 1992; 
Battey et al., 1994; Medh et al., 1995). In our experiments, 
the degradation of ~2Sl-labeled APP,770 was completely 
blocked when RAP was included during the incubation 
period (Figure 2A), suggesting that LRP is likely mediating 
this process. It should be pointed out that while RAP is 
an inhibitor of the LDL receptor, VLDL receptor, and 
gp330, the cell lines used in these experiments do not 
express either the VLDL receptor or gp330. Since the LDL 
receptor is expressed in both cell lines (see below) and 
since the LRP-deficient cells degrade very little APP, the 
LDL receptor does not appear to contribute to the degrada- 
tion of this ligand. 
The catabolism of several LRP ligands, such as lipopro. 
tein lipase (Chappell et al., 1993), hepatic lipase (Kounnas 
et al., 1995), and thrombospondin (Mikhailenko et al., 
1995), is thought to be mediated by a two-step process 
in which initial association of the ligand with cell surface 
proteoglycans may precede the subsequent LRP-medi- 
ated internalization. This initial step is inhibited by heparin, 
and consequently we examined the effect of heparin on 
APPs770 catabolism. The results reveal that inclusion of 
heparin during the experiment prevents the cellular-medi- 
ated degradation of APPs770 (Figure 2A), suggesting that 
cell surface proteoglycans may contribute to the LRP- 
mediated catabolism of this ligand as well. 
The capacity of wild-type cells that express LRP to de- 
grade 1251-labeled APPs770, along with the diminished abil- 
ity of LRP-deficient cells to degrade this ligand, provides 
compelling evidence that LRP mediates the degradation 
of APPs770. To confirm that the LRP-deficient cells are 
capable of catabolizing ligands that interact with other re- 
ceptors, we compared the time course of 1251-labeled LDL 
uptake (Figure 3A) and degradation (Figure 313) with the 
wild-type cells. Little difference in the kinetics and extent 
of uptake and degradation was noted between the two 
cells lines. In contrast, the LRP-dependent ligand c~2M acti- 
vated with methylamine (~2M*) was only taken up (Figure 
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Figure 4. TimeCourse ofthe Cellularlnternal- 
ization and Degradation of ~2SI-Labeled 
APP,770 
Mouse fibroblasts (2 x 10 ~ cells per well) were 
incubated for selected times with ~=Sl-labeled 
APP,770 (1 nM) in the absence of competitor 
(closed circles) or in the presence of either 1 
p,M RAP (open circles) or 100 p.g/ml heparin 
(open squares), The amount of radioactivity in- 
ternalized and degraded was determined at the 
indicated time intervals. Shown is the amount 
of internalization and degradation of l~l- 
labeled APP,770 by LRP-expressing MEF 
cells, shown in (A) and (B), respectively, and 
the internalization and degradation of ~=~l- 
labeled APP,770 by LRP-deficient PEA13 
cells, shown in (C) and (D), respectively. The 
plotted values are means of duplicate determi- 
nations. 
3C) and degraded (Figure 3D) in wild-type cell lines. These 
data demonstrate that the LRP-deficient cells are normal 
in their ability to endocytose ligands via other receptors, 
such as the LDL receptor, but are unable to endocytose 
LRP-dependent ligands; these data are in excellent agree- 
ment with the data of Willnow and Herz (1994). 
We next investigated the time course of cellular uptake 
and degradation of 1251-labeled APP,770. In these experi- 
ments, 1 nM ~2Sl-labeled APP.770 was incubated with fibro- 
blasts for varying times at 37°C. At the indicated time, 
the medium was removed and the amount of ~2Sl-labeled 
APP,770 that had been degraded to acid soluble material 
was measured. The cells were washed and treated with 
proteinase K to release surface-bound radioligand. Radio- 
activity that resisted proteinase K release was considered 
to be intracellular. ~ZSl-labeled APP,770 was internalized 
by cells expressing LRP and approached a steady-state 
intracellular level with time (Figure 4A). Following a lag 
phase, the internalized ligand was degraded, as measured 
by appearance of acid soluble material secreted into the 
medium (Figure 4B). As for previous experiments, both 
the internalization and degradation of ~251-1abeled APP.770 
was inhibited by RAP and heparin. Cells genetically defi- 
cient in LRP internalize and degrade a substantially lower 
amount of ~2Sl-labeled APP,770 than LRP-expressing cells 
(Figures 4C and 4D). Taken together, these data suggest 
that LRP mediates the cellular uptake of APP,770 that 
leads to its degradation. 
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Figure 5. LRP Antibodies Inhibit the Degrada- 
tion of 1251-Labeled APPs770 by Mouse Fibro- 
blasts 
Mouse fibroblasts (2 x 105 cells/well) were in- 
cubated for 18 hr at 37°C with 1=51-labeled 
APPs770 (10 nM) in the absence of competitor 
or in the presence of either heparin (100 p,g/ 
ml), chloroquine (0.1 mM), RAP (1 p.M), affinity- 
purified anti-LRP IgG (100 pg/ml), or control 
IgG against the cytoplasmic domain of LRP 
(100 pglml). Panels show the amount of lzsI- 
labeled APPs770 degraded by mouse fibro- 
blasts expressing LRP (A) or ones deficient in 
LRP expression (B). The data shown are 
means of duplicate determinations _+ SEM. 
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Figure 6. LRP Binds Directly to APP,770 in 
ELISA 
In (A), zinc-coated wells (open circles) or zinc- 
coated wells incubated with APP,770 (closed 
circles) were incubated with the APP=770 
monoclonal antibody 7H5. In (B), increasing 
concentrations ofLRP (0.14-300 nM) were in- 
cubated for 18 hr at 4°C with zinc-coated wells 
(open circles) or zinc.coated wells with cap- 
tured APP,770 (closed circles). In (C), LRP (25 
nM) was incubated with zinc-coated wells 
(open circles) or zinc-coated wells with cap- 
tured APP,770 (closed circles) in the presence 
of increasing concentrations ofRAP (0.2-450 
nM). Bound receptor was detected with the 
monoclonal LRP antibody 8G1. In the absence 
of LRP, there was no binding of 8G1 IgG to 
APP,770-coated wells. Plotted values repre- 
sent means of duplicate determinations. 
To confirm further that LRP is responsible for mediating 
the cellular uptake of APP,770, we used affinity-purified 
polyclonal antibodies against the heavy chain of LRP that 
are known to block the LRP-mediated internalization and 
degradation of ligands (Kounnas et al., 1993, 1995; Mik- 
hailenko et al., 1995). The results, shown in Figure 5A, 
demonstrate that an antibody against the ligand-binding 
domain of LRP greatly diminished the extent of ~2Sl-labeled 
APP,770 that was degraded in cells expressing LRP. A 
control immunoglobulin G (IgG), prepared against the cy- 
toplasmic tail of LRP, was unable to prevent degradation 
of this ligand. The degradation was also blocked by the 
lysosomal enzyme inhibitor chloroquine, confirming that 
the degradation process is lysosomally mediated. 
To measure the ability of LRP to bind directly to 
APPs770, we developed an enzyme-linked immunosor- 
bent assay (ELISA) in which APP,770 was first captured 
on zinc-coated microtiter wells by virtue of its ability to 
bind to zinc (Bush et al., 1993). Increasing concentrations 
of LRP were then added, and the amount of LRP bound 
to the microtiter wells was measured using a monoclonal 
antibody specific for LRP. High affinity binding of the anti- 
body to APPs770-containing wells, but not to wells in which 
APP,770 was omitted, confirms that APP,770 was effec- 
tively captured by the zinc-coated microtiter wells (Figure 
6A). Figure 6B demonstrates the dose response for LRP 
binding to APPs770 captured on microtiter wells. The ap- 
parent KD derived from nonlinear regression analysis of 
the data is 80 nM, which is close to the affinity (55 nM) of 
LRP for another proteinase inhibitor, plasminogen activa- 
tor inhibitor type 1 (PAl-l) (Nykjaer et al., 1994). LRP did 
not bind to microtiter wells in which APP,770 was omitted. 
The binding of LRP to APP,770 captured on zinc-coated 
microtiter plates was inhibited with RAP (Figure 6£;), con- 
sistent with all other known LRP ligands and with our cellu- 
lar degradation for ~251-1abeled APPs770 by LRP-expressing 
cells. These experiments provide direct evidence for a 
high affinity interaction between APP,770 and LRP. 
We were interested to determine whether the formation 
of a proteinase complex with APP,770 enhanced the LRP- 
mediated egradation of this ligand. Previous studies have 
documented that APPs770 is a potent inhibitor of factor 
IXa (Schmaier et al., 1993). We compared the extent of 
LRP-mediated degradation of ~2Sl-labeled APP,770 and 
~2Sl-labeled APP,770 complexed with factor IXa. The re- 
sults, shown in Figure 7, demonstrate that slightly more of 
the ~251-1abeled APP,770-factor IXa complex is degraded 
when compared with ~251-1abeled APP,770. We cannot rule 
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Figure7. l~51-Labeled APPs770-Factor IXa 
Complex Is Degraded by LRP-Expressing 
Cells but Not by LRP-Deficient Cells 
Wells containing 2 × 105 LRP-expressing 
(MEF) or LRP-deficient (PEA13) cells were in- 
cubated with 1251-labeled APPs770 (5 nM) or ~2Sl- 
labeled APPs770-factor IXa (3 nM) for 18 hr at 
37°C in the absence of competitor r in the 
presence of 1 p.M RAP. The amount of 1251- 
labeled APPs770 or l~l-labeled APPs770--fac- 
tor IXa degraded by LRP-expressing MEF cells 
is shown in (A) and that by LRP-deficient 
PEA13 cells in (B). Plotted values represent 
means of duplicate determinations. 
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out the possibility that APP,770 is reacting with protein- 
ases prior to its LRP-mediated uptake and thus that com- 
plex formation of APP,770 with proteinases may be re- 
quired for optimal catabolism of the complex. However, 
reaction with proteinases does not appear to be required 
for binding, since APP,770 can bind to LRP directly (see 
Figure 6). In this regard, APP,770 is similar to another 
proteinase inhibitor, PAl-l, that can bind to LRP in the 
absence of proteinases (Nykjaer et al., 1994). 
It is apparent hat LRP contains multiple, noninteracting 
ligand-binding sites (Williams et al., 1992; Willnow et al., 
1992). To determine whether apoE could compete for the 
LRP-mediated degradation of ~Sl-labeled APP,770, we 
performed competition experiments. In these experi- 
ments, 15VLDL was first enriched with apoE3 or apoE4 to 
generate apoE-enriched particles that are known to bind 
to LRP (Kowal et al., 1989). Cells were then incubated 
with ~51-1abeled APP,770 in the presence and absence of 
excess apoE-enriched I~VLDL, and the effect on degrada- 
tion of the labeled ligand was measured. The results, 
shown in Figure 8, demonstrate that I~VLDL enriched with 
either apoE3 or apoE4 had a slight inhibitory (approxi- 
mately 20%) effect on APP,770 degradation. No differ- 
ence between the two isoforms of apoE was noted. On 
the other hand, 15VLDL alone, which does not bind to LRP, 
had no effect on APP,770 catabolism. Consistent with our 
previous experiments, the degradation of ~Sl-labeled 
APP,770 is greatly diminished in cells that lack LRP (Fig- 
ure 8B). These results suggest that APP,770 and apoE- 
enriched I~VLDL bind to distinct ligand-binding sites on 
LRP. The partial inhibition noted may be the result of a 
steric effect due to the large size of the ~VLDL particle, 
although other mechanisms cannot be ruled 
Discuss ion  
The results presented in this paper indicate that the endo- 
cytic receptor LRP is a mediator of the cellular catabolism 
of APP,770. This conclusion is supported by several inde- 
pendent lines of evidence. First, ~2Sl-labeled APPs770 is 
endocytosed and degraded by fibroblasts that express 
LRP and is greatly reduced in fibroblasts deficient in LRP. 
Second, the cellular degradation of ~2Sl-labeled APP,770 
is blocked by RAP, an inhibitor of LRP function. Third, the 
cellular degradation of 12Sl-labeled APPs770 is blocked by 
antibodies against the LRP ligand-binding regions, but not 
by antibodies prepared against the LRP cytoplasmic do- 
main. Fourth, we demonstrated a high affinity interaction 
between APP,770 and purified LRP. This interaction was 
inhibited by RAP. Consistent with the effect of heparin on 
other LRP ligands, heparin is an effective antagonist of the 
cellular catabolism of ~Sl-labeled APP,770. At this time, it 
is not known whether heparin directly inhibits the binding 
of APP,770 to LRP or whether it prevents the association of 
APP,770 to cell surface proteoglycans, which may assist in 
the LRP-mediated uptake of APP,770. In this regard, the 
catabolism of several LRP ligands (e.g., thrombospon- 
din-1 [Mikhailenko et al., 1995; Godyna et al., 1995], lipo- 
protein lipase [Chappell et al., 1993], and hepatic lipase 
[Kounnas et al., 1995]) seem to be facilitated by interac- 
tion with cell surface proteoglycans. It is possible that 
APP,770, like other LRP ligands, first binds to cell surface 
proteoglycans and is then transferred to LRP for subse- 
quent internalization. 
Finally, our data indicate that LRP appears specific for 
the KPI-containing form of APP and that APP,770 com- 
plexed to proteinases is also internalized by LRP. This 
is consistent with the role of LRP in removing inhibited 
proteinases, such as a~M-proteinase complexes (Ashcom 
et al., 1990) and complexes of serpins with their target 
proteinase (Nykjaer et al., 1992; Orth et al., 1992; Poller et 
al., 1995). Taken together, these data provide compelling 
evidence that LRP is responsible for APPJ70 uptake lead- 
ing to its lysosomal degradation. 
Like LRP, other members of the LDL receptor, such as 
the VLDL receptor (Argraves et al., submitted) and gp330 
A LRP-expressing cells 
8r" 
-~ 7, 
6' it} 
o 
5 
"O 
-o 4 
3 
"O 
2 
o 1 
j ..j _1 nr "$ > > > 
E ¢o ~- 
O I~1 I.U 
O O O 
O ~- Q" z '~ 
B LRP-deficient cells 
~ m  ~ T 
.~ --t .-t .-I O. .- o E3 i"1 _1 _1 rr ~, > > 
E o~ ,~- o Lu ILl 
o o o 
o Q- ,.-t 
Z < '< 
80 
70 
60 
50 
40 
30 
20 
10 
0 
o 
I,O 
O 
"O 
"O 
"O 
~J 
m 
O 
Figure 8. Effect of ApoE Isoforms on the Deg- 
radation of 12%Labeled APP,770 by Mouse Fi- 
broblasts 
Mouse fibroblasts (2 x 105) were incubated for 
18 hr at 37°C with 1251-labeled APPs770 
(8.8 nM) in the absence of competitor  in the 
presence of either RAP (1 p.M)), 10 pg/ml 
apoE3-I3VLDL, 10 pg/ml apoE4-iSVLDL, or 10 
pg/ml ~VLDL. The concentration of apoE- 
enriched ~VLDL represents he ~,VLDL protein 
before nrichment with apoE. Panels show the 
amount of ~251-1abeled APP,770 degradation by 
mouse fibroblasts expressing LRP (A) or defi- 
cient in LRP expression (B). The data shown 
are means of duplicate determinations -+ 
SEM. The inhibition was statistically significant 
for both apoE3-~,VLDL and apoE4-I3VLDL and 
for RAP (F[4,t5] = 21.65); Fisher protected 
least significant difference post hoc test 
showed that both apoE3-~VLDL and apoE4- 
~,VLDL were different from ~VLDL alone (p < 
0.05 for both) but not from each other. RAP 
was also significantly different than all other 
categories (p < 0.001). 
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(Willnow et al., 1992), also bind multiple ligands. While 
these receptors have overlapping ligand specificity, they 
exhibit a different pattern of expression. LRP is widely 
expressed but prominent in liver and brain (Moestrup et 
al., 1992) and VLDL receptor in heart, muscle, adipose 
tissue, and brain (Sakai et al., 1994); gp330 is prominently 
expressed in specialized epithelia of the brain, lung, and 
kidney (Zheng et al., 1994; Kounnas et al., 1994). Because 
of their similar metabolic function, these receptors may 
also bind to APPs770 and contribute to its clearance. 
We have not yet determined whether the integral mem- 
brane form of APP can interact with LRP. APP follows at 
least two posttranslational processing pathways during its 
biosynthesis. In its constitutive secretory pathway (Esch 
et al., 1990; Sisodia et al., 1990), APP is cleaved within 
the ectodomain to give rise to secreted APP. Alternatively, 
APP can be internalized from the cell surface and targeted 
to the lysosomal compartment, where proteolytic frag- 
ments containing the AI3 peptide appear to be generated 
(Golde et al., 1992; Haass et al., 1992). The ability of LRP 
to bind and mediate internalization of APPs770 makes it 
plausible that LRP can also bind the integral membrane 
form of APP. We hypothesize that LRP facilitates targeting 
of APP to lysosomal compartments and thus may promote 
AI3 production by mediating the internalization and lyso- 
somal degradation of APP. If so, modulators of the expres- 
sion or function of LRP may affect AI3 production. 
While the precise physiological role of APP remains to 
be established, the collective data support an important 
role for this molecule in neuronal function. Secreted forms 
of APP have been demonstrated to have a neuroprotective 
effect (Mattson et al., 1993). APP mRNA levels are ele- 
vated following neuronal injury (Abe et at., 1991), and KPI- 
containing forms are elevated during aging (Koo et al., 
1990). Protein levels of KPI-containing soluble APP forms 
may also be increased relative to non-KPI-containing 
forms in AD brains (R. D. M., T. Lynch, A. I. B., S. Whyte, A. 
Henry, S. Portbuly, G. Maltarp, T. H. Small, K. Beyreuther, 
and C. L. Masters, unpublished data). APP has also been 
suggested to play a role in promotion of neurite outgrowth 
(Breen et al., 1991; Breen, 1992) and involves both the 
KPI domain and other portions of the APP ectodomain 
(Jin et al., 1994; Quiet  al., 1995). Together, these data 
support an important role for APP in neurite outgrowth 
and response to injury. 
ApoE, like APP, also appears to play an important role in 
neuronal function and has been demonstrated to promote 
neurite outgrowth (Nathan et al., 1994) via what appears 
to be an LRP-mediated mechanism (Mahley, 1995). ApoE 
is also increased following neural damage (Poirier et al., 
1993; Mahley, 1988). It is our hypothesis that both apoE 
and APP bind and target molecules for LRP-mediated up- 
take in normal neuronal function and after neuronal injury. 
In the brain, LRP is present on neurons and reactive, but 
not resting astrocytes (Rebeck et al., 1993). Interestingly, 
LRP, APP, APLP1, and APLP2 are all concentrated in 
synaptic fractions prepared from human brain (T. W. Kim, 
M. DiFiglia, W. Wasco, G. W. Rebeck, B. T. H., D. K. S., 
and R. E. T., unpublished data). Thus, LRP is localized 
at appropriate anatomical sites, which suggests a role in 
the critical balance of proteinase and proteinase inhibitor 
production and turnover required for synaptic integrity. 
Disruption of this regulation could contribute to the synap- 
tic degeneration in AD. 
With the identification of APP,770 as a novel LRP ligand, 
it is now evident that LRP serves as a receptor for two 
molecules, APP and apoE, for which specific genetic vari- 
ants have been shown to be genetically linked or tightly 
associated with cases of familial and sporadic AD. A simi- 
lar catabolic pathway for apoE and APPs770 provides a 
biochemical link between these two proteins. Whether this 
catabolic pathway contributes to the pathophysiology of 
AD is unknown. However, these observations may lead 
to insight into the molecular basis of AI~ generation and 
of the role of apoE in neurodegeneration i AD. 
Experimental Procedures 
Proteins 
Human APP,770 and APP,695 were purified essentially according to 
the method of Moir et al. (1992) from the conditioned medium of Chi- 
nese hamster ovary cells transfected with a construct containing the 
human APP770 or APP695 cDNA (Sisodia et al., 1990). The purifica- 
tion procedure ntails a sequential series of chromatography steps: 
Q-Sepharose, heparin-Sepharose, Mono Q, and phenyI-Superose. 
Secreted APP fractions were concentrated and desalted into 20 mM 
Tris, 150 mM NaCI (pH 7.4) on Centricon 50 protein concentrators 
(Amicon, Beverly, MA), and protein concentration was determined by 
the bicinchoninic acid protein assay (Pierce Chemical Company, Rock- 
ford, IL). Purity of APP,770 and APP,695 preparations was evaluated 
by staining SDS-polyacrymalide g ls with silver reagents for protein 
and by amino-terminal sequencing. Radioiodination fsecreted APP 
preparations was performed using Na[12Sl]iodine (Amersham Corpora- 
tion, Arlington Heights, IL) and iodogen reagent (Pierce Chemical 
Company, Rockford, IL) to obtain specific activities ranging from 10 
to 20 p.Ci/pg protein. Following radiolabeling, unincorporated iodine 
was separated from 1251-labeled proteins on a Sephadex G25 PD10 
column (Pharmacia Biotech, Piscataway, N J) equilibrated with 1% 
BSA, 50 mM Tris, 150 mM NaCI (pH 8.0) (-IBS). The integrity of the 
radiolabeled APP,770 and APP,695 was evaluated by electrophoresis 
on 4%-12% polyacrylamide gradient gels (Novex, San Diego, CA), 
followed by autoradiograpy. For all experiments described herein, ~251- 
labeled APP was used within 4 hr of radiolabeling. Factor IXa was 
purchased from Enzyme Research Laboratories (South Bend, IN). 
Complexes of APP,770 with factor IXa were formed by incubation of 
l~51-1abeled APPJ70 and factor IXa (1:0.5 molar atio) for 1 hr at 25°C. 
LRP was isolated from detergent extracts of human placenta by ~2M*- 
Sepharose affinity chromatography as described previously (Ashcom 
et al., 1990). a2M * was prepared as described elsewhere (Ashcom et 
al., 1990). Human RAP, expressed in bacteria s a fusion protein 
with glutathione S-transferase (GST), was prepared free of GST as 
described previously (Williams et al., 1992). ApoE3 was provided by 
Dr. J. Harmony (University of Cincinnati College of Medicine, Cincin- 
nati, OH). ApoE4 was purchased from Calbiochem (San Diego, CA). 
!SVLDL was provided by Dr. R. Mahley (Gladstone Institute of Cardio- 
vascular Disease, San Francisco, CA). Complexes of apoE and I~VLDL 
were formed by incubation of J3VLDL and apoE (1:4 protein ratio) for 
1 hr at 25°C. LDLs were provided by Dr. D. Chappell (University of 
Iowa College of Medicine, Iowa City, Iowa). BSA, fraction V, was pur- 
chased from Sigma Chemical Company (St. Louis, MO). 
Antibodies 
The mouse monoclonal ntibody to the KPI domain of APP, designated 
7H5, has been described previously (Hyman et al., 1992) and was 
provided by Dr. D. Schenk (Athena Neurosciences, South San Fran- 
cisco, CA). The mouse monoclonal ntibodies to APP, 2;2C11 and AIz 
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90, were purchased from Soehringer Mannheim (Indianapolis, IN). 
The mouse monocional antibodyto the heavychain of LRP, designated 
8G1, and the rabbit polyclonal antibodies to both the 515 kDa heavy 
chain of LRP (R777) and to a synthetic peptide from the cytoplasmic 
domain of the 85 kDa light chain of LRP (R704) have been described 
previously (Strickland et al., 1990; Kounnas et al., 1992b). Affinity 
selection of LRP IgG was accomplished by LRP-Sepharose affinity 
chromatography. IgG was selected from R704 serum by protein 
G-Sepharose chromatography. 
Cells 
A normal mouse embryo fibroblast line, designated MEF, and a mouse 
embryo fibroblast line genetically deficient in LRP, designated PEA13, 
were obtained from Dr. J. Herz (University of Texas Southwestern 
Medical Center, Dallas, TX) and maintained as described elsewhere 
(Willnow and Herz, 1994). For secreted APP uptake and degradation 
experiments, cells were plated at 2 x 105 cells per well and grown 
for 18 hr at 37°C in 50/o CO2 in 12-well dishes. Cells were incubated 
with 1% Nutridoma (Boehringer Manneheim, Indianapolis, IN), in 20 
mM HEPES (pH 7.4), penicillin/streptomycin, 1.5°/o BSA (assay me- 
dium) for 1 hr prior to the addition of 1251-labeled APPs770 along with 
competitors (RAP [1 pM], antibodies [100 p.g/ml], or heparin [100 pg/ 
ml]). Chloroquine (0.1 mM; Sigma Chemical Company, St. Louis, MO) 
was added with radiolabeled ligand to inhibit its lysosomal degrada- 
tion. Determination of the amount of radiolabeled APP,770 internalized 
or degraded was done as described previously (Kou nnas et al., 1995). 
In brief, degradation was taken as radioligand in the cell culture me- 
dium that was soluble in 10% trichloroacetic acid and was corrected 
for noncellular-mediated degradation that occurred in parallel wells 
lacking cells. The amount of radioligand that was internalized by cells 
was defined as the amount of radioactivity that remained associated 
with the cell pellet following trypsin-EDTA, proteinase K (Sigma Chem- 
ical Company, St. Louis, MO) treatment. 
Immunoassays 
ELISAs were performed using APP~770 captured on zinc-coated plates 
(R. D. M., A. I. B., K. M. Rosenkronz, L° Roder, and R. E. T., unpub- 
lished data). Zinc was immobilized on the plastic surface of microtiter 
wells through covalently attached nitrotriacetic acid groups. The effi- 
ciency of APP,770 capture through immobilized zinc was determined 
to be 2- to 3-fold higher when compared with APPs770 absorption to 
plastic directly. For the ELISA, microtiter wells coated with zinc were 
incubated with APP,770 or SSA (2 p.g/ml) in for 3 hr at 37°C. Unoccu- 
pied binding sites were blocked with 3% BSA, TBS, 10 p.M ZnCI2, 2 
mM MgCI2, 2 mM CaCI2 (blocking buffer) for 1 hr at 25°C. Various 
concentrations of LRP (0.14-300 nM) in blocking buffer containing 
0.05o/O Tween 20 were incubated with coated wells for 18 hr at 4°C. 
For ELISAs that measured the effects of RAP on LRP binding to 
APP,770, wells coated with APPs770 were incubated with LRP (25 
nM) in the presence of increasing concentrations of RAP (0.2-450 
nM). Following the incubation, the wells were washed and incubated 
with the LRP monoclonal antibody 8G1 in blocking buffer containing 
0.05% Tween 20 followed by goat anti-mouse IgG conjugated to perox- 
idase (Sigma Chemical Company, St. Louis, MO) and the chromogenic 
substrate 3,3',5,5'-tetramethylbenzidine (Kirkegaard and Perry Labo- 
ratories, Gaithersburg, MD). Immunoblotting was performed as de- 
scribed previously (Battey et al., 1994). 
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